Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease

V. Tabar (), H. Sarva, A. M. Lozano, A. Fasano, S. K. Kalia, K. K. H. Yu, C. Brennan, Y. Ma, S. Peng, D. Eidelberg, M. Tomishima, S. Irion, W. Stemple, N. Abid, A. Lampron, L. Studer and C. Henchcliffe
Additional contact information
V. Tabar: Memorial Sloan Kettering Cancer Center
H. Sarva: Weill Cornell Medicine
A. M. Lozano: University of Toronto
A. Fasano: Krembil Brain Institute
S. K. Kalia: University of Toronto
K. K. H. Yu: Memorial Sloan Kettering Cancer Center
C. Brennan: Memorial Sloan Kettering Cancer Center
Y. Ma: Feinstein Institutes for Medical Research
S. Peng: Feinstein Institutes for Medical Research
D. Eidelberg: Feinstein Institutes for Medical Research
M. Tomishima: BlueRock Therapeutics
S. Irion: BlueRock Therapeutics
W. Stemple: BlueRock Therapeutics
N. Abid: BlueRock Therapeutics
A. Lampron: BlueRock Therapeutics
L. Studer: Sloan Kettering Institute
C. Henchcliffe: University of California

Nature, 2025, vol. 641, issue 8064, 978-983

Abstract: Abstract Parkinson’s disease is a progressive neurodegenerative condition with a considerable health and economic burden1. It is characterized by the loss of midbrain dopaminergic neurons and a diminished response to symptomatic medical or surgical therapy as the disease progresses2. Cell therapy aims to replenish lost dopaminergic neurons and their striatal projections by intrastriatal grafting. Here, we report the results of an open-label phase I clinical trial (NCT04802733) of an investigational cryopreserved, off-the-shelf dopaminergic neuron progenitor cell product (bemdaneprocel) derived from human embryonic stem (hES) cells and grafted bilaterally into the putamen of patients with Parkinson’s disease. Twelve patients were enrolled sequentially in two cohorts—a low-dose (0.9 million cells, n = 5) and a high-dose (2.7 million cells, n = 7) cohort—and all of the participants received one year of immunosuppression. The trial achieved its primary objectives of safety and tolerability one year after transplantation, with no adverse events related to the cell product. At 18 months after grafting, putaminal 18Fluoro-DOPA positron emission tomography uptake increased, indicating graft survival. Secondary and exploratory clinical outcomes showed improvement or stability, including improvement in the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III OFF scores by an average of 23 points in the high-dose cohort. There were no graft-induced dyskinesias. These data demonstrate safety and support future definitive clinical studies.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41586-025-08845-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:641:y:2025:i:8064:d:10.1038_s41586-025-08845-y

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-025-08845-y

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().